Hisamitsu To Acquire Transdermal Patch Firm Noven; Next Step: Novartis JV Buyout?
This article was originally published in PharmAsia News
Executive Summary
Japanese transdermal patch firm Hisamitsu appears to be buying a $428 million bargaining date with Novartis with its purchase of Miami-based Noven, which has a buy-sell clause in its vital Novogyne joint venture with Novartis